Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U01HL142107 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Clinical Directors Network | NETWORK |
| University of Texas | OTHER |
| National Heart, Lung, and Blood Institute (NHLBI) | NIH |
Not provided
Not provided
Not provided
Not provided
The overall objective of this project is to develop and rigorously test implementation strategies to address the gap in scientific knowledge of lower use of evidence-based interventions commonly referred to as the ABCS (aspirin, blood pressure control, cholesterol control, and smoking cessation)which contributes to the growing CVD morbidity and mortality among PLH.
Our project has two major aims:
Aim 1: To assess the impact of the implementation of an evidence-based, multilevel strategy to reduce cardiovascular vascular disease (CVD) among PLH.
Aim 2: To assess the process of implementation of these strategies using RE-AIM QuEST. Using both quantitative and qualitative methods, we evaluate the process of implementation by assessing Reach, [Effectiveness addressed in Aim 1], Adoption, Implementation and Maintenance whilst integrating Qualitative Evaluation for Systematic Translation.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control | No Intervention | CVD risk prior to the patient and clinician training | |
| Training | Experimental | CVD risk after the patient and clinician training |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ABCS training | Behavioral | Clinicians and patients will be given information regarding the ABCS (Aspirin, Blood Pressure control,Cholesterol control, and Smoking Cessation) and for reducing CVD risk among HIV patients. |
| Measure | Description | Time Frame |
|---|---|---|
| 10-year CVD risk reduction | This will be based on the ACVSD risk calculator | 12 months |
Not provided
Not provided
Inclusion Criteria:
Sites:
Patients:
Clinicians:
Exclusion Criteria:
Patients:
Clinicians:
• Planning to leave the site within the next 12 months
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Kevin Fiscella, MD, MPH | University of Rochester | Principal Investigator |
| Jonathan Tobin, PhD | Clinical Directors Network, Inc; Albert Einstein College of Medicine | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Rochester | Rochester | New York | 14642 | United States |
Not provided
A stratified clustered randomized stepped wedge design.
Not provided
Not provided
Not provided
Not provided